99 HIGH STREET, 30TH FLOOR, BOSTON, MA
Other Events
Praxis Precision Medicines Dismisses Ernst & Young as Auditor
Praxis Precision Medicines Elects Class III Directors at Annual Meeting
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities